Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

This report summarizes updates to recommended 13-valent pneumococcal conjugate vaccine (PCV13) in series with 23-valent polysaccharide vaccine (PPSV23). The Advisory Committee on Immunization Practices recommends: 

• Adults age 65 years and older should receive a single dose of PPSV23
• Adults age 65 years and older who don’t have an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant and who haven’t received PCV13 before should decide with their health care provider whether to receive PCV13
• If the adult and health care provider decide to administer PCV13, PPSV23 should be given at least 1 year later

This report also explains that PCV13 for children has greatly reduced pneumococcal disease among people across age groups.